Amgen | AMGN - Operating Profit


Amgen reported $4.68B in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 268.42M 20.01M Sep/2026
Genmab DKK 407M 182M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Glaxosmithkline GBP 2.13B 166M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Moderna USD 130M 945M Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 392M Sep/2026
Novartis USD 1.84B 2.39B Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
Teva Pharmaceutical Industries USD 1.19B 954M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026